Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, B; Harrington, KJ; Greil, R; Soulieres, D; Tahara, M; de Castro, G; Psyrri, A; Baste, N; Neupane, P; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Hong, RL; Mendoza, RG; Roy, A; Zhang, YY; Gumuscu, B; Cheng, JD; Jin, F; Rischin, D

View this publication in the PUBMED database